Javier Torres-Cortes

Javier Torres-Cortes

Auto-generated profile, based on publicly available information

Javier Torres-Cortes

Institute of Psychiatry, Psychology & Neuroscience, King's College London, United Kingdom; Universidad de Alcalá, Hospital Universitario Ramón y Cajal, Ramón y Cajal Health Research Institute (IRYCIS), Madrid, Spain

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2026 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Open access
JTJavier Torres-Cortes
Javier Torres-Cortes
JCJuan Chart-Pascual
Juan Chart-Pascual
CAClaudia Aymerich
Claudia Aymerich
OKOzge Karakus-Guvenir
Ozge Karakus-Guvenir
ASAditya Narain Sharma
Aditya Narain Sharma
GPGonzalo Salazar de Pablo
Gonzalo Salazar de Pablo
To comprehensively synthesize the meta-analytic evidence regarding bipolar spectrum disorder (BSD) in children and adolescents. PRISMA-compliant umbrella review (PROSPERO:CRD420250651065) across multiple databases to identify meta-analyses involving children and adolescents with BSD. Literature search, screening, data extraction, and quality assessment (via AMSTAR-2) were performed independently. Findings were synthesized and grouped according to key clinical, cognitive, biological and treatment domains. Fifty-two meta-analyses were included (k=754, N=59,967, age=13.0 years, 44.8% female participants). Most reported symptoms were increased energy (79%, 95% confidence interval (CI)=61-93%), irritability (77%, 95%CI=64-88%), and mood lability (76%, 95%CI=55-92%). Psychiatric comorbidities were common, with attention-deficit/hyperactivity disorder being most frequent (53%, 95%CI=36-70%). Treatment delay was longer in children and adolescents than in adults with BSD (SMD=0.39, 95%CI=0.15-0.64). 26.2% (95%CI=24.4-28.0) of children and adolescents with BSD attempted suicide at least once, with higher risk vs. children and adolescents with depression (OR=1.59; 95%CI=1.24-2.05) and adult-BSD (OR=1.68, 95%CI=1.29-2.18). Compared to healthy controls (HCs), children and adolescents with BSD showed neurocognitive impairments. Abnormalities in neuroimaging markers were significant in children and adolescents with BSD vs. HCs, children and adolescents with depression and adult-BSD. Second-generation antipsychotics (SMD=0.68, 95%CI=0.51-0.86) and mood stabilizers (SMD=0.61, 95%CI=0.40-0.82) were superior for mania vs. placebo. Cognitive behavioral therapy (CBT) was associated with improvements in manic and depressive symptoms. BSD in children and adolescents is linked to illness severity, cognitive deficits, and neuroimaging abnormalities, requiring integrated pharmacological and psychosocial interventions (e.g. CBT). SGAs effectively treat mania, but options for depression remain limited. More prognostic and long-term studies are needed.